{"filing":{"accession_number":"0001156039-26-000049","cik":"0001156039","ticker":"ELV","company_name":"Elevance Health, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"elv-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1156039/000115603926000049/elv-20260610.htm"},"events":[{"id":5632,"run_id":4935,"accession_number":"0001156039-26-000049","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The filing discloses reaffirmation of full-year 2026 earnings guidance ($19.85 per diluted share including unfavorable items; $26.75 adjusted) and benefit expense ratio guidance (90.2% ± 50 bps) during investor meetings. While this is forward-looking guidance rather than an earnings release (which typically reports historical results), the reaffirmation of specific quantitative earnings and operational metrics would materially affect a reasonable investor's assessment of the company's expected financial performance. This does not fit cleanly into earnings_release (no historical results reported) but is material guidance disclosure that warrants classification as other_material.","company_name":"Elevance Health, Inc.","ticker":"ELV","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5703,"accession_number":"0001156039-26-000049","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses reaffirmation of full-year 2026 earnings guidance ($19.85 per diluted share including unfavorable items; $26.75 adjusted) and benefit expense ratio guidance (90.2% ± 50 bps) during investor meetings. While this is forward-looking guidance rather than an earnings release (which typically reports historical results), the reaffirmation of specific quantitative earnings and operational metrics would materially affect a reasonable investor's assessment of the company's expected financial performance. This does not fit cleanly into earnings_release (no historical results reported) but is material guidance disclosure that warrants classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:06:15.508453+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5703,"accession_number":"0001156039-26-000049","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses reaffirmation of full-year 2026 earnings guidance ($19.85 per diluted share including unfavorable items; $26.75 adjusted) and benefit expense ratio guidance (90.2% ± 50 bps) during investor meetings. While this is forward-looking guidance rather than an earnings release (which typically reports historical results), the reaffirmation of specific quantitative earnings and operational metrics would materially affect a reasonable investor's assessment of the company's expected financial performance. This does not fit cleanly into earnings_release (no historical results reported) but is material guidance disclosure that warrants classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:06:15.508453+00:00","company_name":"Elevance Health, Inc.","ticker":"ELV","filing_date":"2026-06-10"}]}